Ehave Inc. (OTCMKTS:EHVVF) has announced KetaDASH www.ketadash.com which is an intravenous based home delivery platform for Ketamine prescriptions.
Ehave giving practitioners a way to administer ketamine
The company has signed an asset purchase agreement for the acquisition of tangible and intangible assets of IV therapy service CureDash www.curedash.com. Currently, Curedash runs an IV platform which will become KetaDash’s backbone. Most importantly, KetaDASH will offer medical practitioners a platform for intravenous administration of Ketamine for patients at home. Practitioners currently use ketamine to ease pain and also enables efficacy of sedatives at lower doses thus minimizing the potential amount of addictive pain medication necessary for some medical procedures. Studies are currently ongoing on Ketamine as a major depression treatment but ii is yet to receive FDA approval for treatment of depression.
The KetaDASH platform includes staffing, software, equipment, and protocols. Ehave has designed an intuitive and smart dashboard where associated nurses and clients can access detailed insight into how Ketamine therapy works. Interestingly patients can create a profile where they can schedule appointments and check on administering nurses’ availability.
There has been an increase in ketamine in recent times according to the Multidisciplinary Association for Psychedelics. Ketamine is a synthetic compound with antidepressant properties and was initially developed as a short-acting anesthetic in the 1960s. However, it has emerged as a potential therapy for depression resistant to treatments and showed benefits in bipolar and unipolar depression treatment.
Ketamine use in depression treatment growing
Ehave medical Advisor, Victor Dorodny said that ketamine is commonly used as an anesthetic medical but has seen growing use in treating depression, chronic pain, suicidality, OCD, migraines, and PTSD symptoms. He added that for most this is a huge breakthrough as Ketamine represents an opportunity to manage mental health challenges.
Ben Kaplan the company’s CEO said that the company has expanded into telehealth and psychedelics in the past year. He said that KetaDASH will offer potential lifesaving Ketamine infusion therapy for psychedelic disorders treatment such as bipolar disorder, major depressive disorder, and PTSD. The platform will also allow Ehave to grow revenue.
